ReviewCurrent microbiology2023
Acinetobacter baumannii Bacteriophage: Progress in Isolation, Genome Sequencing, Preclinical Research, and Clinical Application.
Review in Current microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Evolutionary dynamics and research hotspots of phage applications againstFrontiers in microbiology · 2025Pooled it
- Genomic landscape of 340 virulent Acinetobacter bacteriophages reveals anti-CRISPR-enriched candidates for therapeutic prioritization.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Synergistic effects of halo-plaque forming phage cocktails against polymicrobialMicrobiology spectrum · 2026Article
- Isolation, characterization and genomic insights of the lytic bacteriophage TANUVAS_MVC-VPH-AB targeting Acinetobacter spp. with antibacterial and anti-biofilm activity.Molecular biology reports · 2026Article
- Engineering T3 and T7 host range to target protein receptors and guide bacterial evolution.iScience · 2026Article
- Treating Extensively Drug-ResistantPathogens (Basel, Switzerland) · 2026Review
- Phage-quinolone synergy: mechanisms, clinical strategies, and translational prospects.Frontiers in microbiology · 2026Review
- Characterization of phage AbpL with a terminally redundant genome and its therapeutic potential against drug-resistantFrontiers in cellular and infection microbiology · 2026Article
- Genomic, Functional, and Evolutionary Insights into a Novel T7-like Phage B1 Infecting Multidrug-ResistantInternational journal of molecular sciences · 2025Article
- Phage Therapy forAntibiotics (Basel, Switzerland) · 2025Review
- Bacteriophage therapy to combat MDR non-fermenting Gram-negative bacteria causing nosocomial infections: recent progress and challenges.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Acinetobacter phages use distinct strategies to breach the capsule barrier.PLoS pathogens · 2025Article
- Isolation and characterization of phages ΦZC2 and ΦZC3 against carbapenem-resistant Acinetobacter baumannii, and efficacy of ΦZC3 on A549 cells.Virology journal · 2025Article
- Beyond antibiotics: mesenchymal stem cells and bacteriophages-new approaches to combat bacterial resistance in wound infections.Molecular biology reports · 2024Review
- A review of the fighting Acinetobacter baumannii on three fronts: antibiotics, phages, and nanoparticles.Molecular biology reports · 2024Review
- Current treatment strategies for targeting virulence factors and biofilm formation inFuture microbiology · 2024Review
- Isolation and Characterization of Novel Bacteriophages to Target Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Stability study in selected conditions and biofilm-reducing activity of phages active against drug-resistant Acinetobacter baumannii.Scientific reports · 2024Article
- Characterization of bacteriophage vB_AbaS_SA1 and its synergistic effects with antibiotics against clinical multidrug-resistant Acinetobacter baumannii isolates.Pathogens and disease · 2024Article
- Characterization and efficacy against carbapenem-resistantFrontiers in cellular and infection microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Acinetobacter baumannii (A. baumannii) is a common nosocomial pathogen associated with serious clinical challenges owing to its rapidly increasing resistance to antibiotics. Due to their high host specificity and easy access to the natural environment, bacteriophages (phages) may serve as good antibacterial agents. Phage therapy has been successfully used to treat antibiotic-resistant A. baumannii infections. As a fundamental step before phage therapy, the characterization and sequencing of A. baumannii phages have been well studied. Until October 2022, 132 A. baumannii phages have been sequenced and studied, with their genomes ranging from 4 to 234 kb, and we summarize the characterized and sequenced A. baumannii phages. This review is a current and short overview that does not go into detail on the A. baumannii phages. In addition, preclinical studies and clinical applications of A. baumannii phages are also included.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.